These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33428214)

  • 1. Efficacy of salbutamol monotherapy in slow-channel congenital myasthenic syndrome caused by a novel mutation in CHRND.
    Tawara N; Yamashita S; Takamatsu K; Yamasaki Y; Mukaino A; Nakane S; Farshadyeganeh P; Ohno K; Ando Y
    Muscle Nerve; 2021 Apr; 63(4):E30-E32. PubMed ID: 33428214
    [No Abstract]   [Full Text] [Related]  

  • 2. Salbutamol monotherapy in acetylcholine receptor deficiency-related congenital myasthenic syndrome due to CHRNE mutation.
    Dutta A; Chakraborty A; Das S; Dubey S; Pandit A
    J Neurol; 2022 Jul; 269(7):3923-3925. PubMed ID: 35175423
    [No Abstract]   [Full Text] [Related]  

  • 3. Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome.
    Peyer AK; Abicht A; Heinimann K; Sinnreich M; Fischer D
    Neuromuscul Disord; 2013 Jul; 23(7):571-4. PubMed ID: 23688972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK.
    Gallenmüller C; Müller-Felber W; Dusl M; Stucka R; Guergueltcheva V; Blaschek A; von der Hagen M; Huebner A; Müller JS; Lochmüller H; Abicht A
    Neuromuscul Disord; 2014 Jan; 24(1):31-5. PubMed ID: 24183479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital myasthenia syndrome with demyelinating sensorimotor neuropathy responsive to salbutamol monotherapy: a novel clinical phenotype of CHRNE mutation.
    Ghosh R; Dubey S; Roy D; Mayo S; Benito-León J
    Neurol Sci; 2024 Jul; 45(7):3555-3558. PubMed ID: 38411853
    [No Abstract]   [Full Text] [Related]  

  • 6. Congenital myasthenic syndromes.
    Engel AG
    Handb Clin Neurol; 2008; 91():285-331. PubMed ID: 18631848
    [No Abstract]   [Full Text] [Related]  

  • 7. A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment.
    Webster RG; Cossins J; Lashley D; Maxwell S; Liu WW; Wickens JR; Martinez-Martinez P; de Baets M; Beeson D
    Exp Neurol; 2013 Oct; 248():286-98. PubMed ID: 23797154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders.
    Clausen L; Cossins J; Beeson D
    J Neuromuscul Dis; 2018; 5(2):231-240. PubMed ID: 29865088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.
    McMacken GM; Spendiff S; Whittaker RG; O'Connor E; Howarth RM; Boczonadi V; Horvath R; Slater CR; Lochmüller H
    Hum Mol Genet; 2019 Jul; 28(14):2339-2351. PubMed ID: 31220253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare slow channel congenital myasthenic syndromes without repetitive compound muscle action potential and dramatic response to low dose fluoxetine.
    Durmus H; Sticht H; Ceylaner S; Hashemolhosseini S; Deymeer F
    Acta Neurol Belg; 2021 Dec; 121(6):1755-1760. PubMed ID: 33030681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies for congenital myasthenic syndromes.
    Lee M; Beeson D; Palace J
    Ann N Y Acad Sci; 2018 Jan; 1412(1):129-136. PubMed ID: 29381222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine.
    Colomer J; Müller JS; Vernet A; Nascimento A; Pons M; Gonzalez V; Abicht A; Lochmüller H
    Neuromuscul Disord; 2006 May; 16(5):329-33. PubMed ID: 16621558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol.
    Chan SH; Wong VC; Engel AG
    Pediatr Neurol; 2012 Aug; 47(2):137-40. PubMed ID: 22759693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOK7 congenital myasthenic syndrome responsive to oral salbutamol.
    Tayade K; Salunkhe M; Agarwal A; Radhakrishnan DM; Srivastava AK
    QJM; 2022 May; 115(5):323-324. PubMed ID: 35092298
    [No Abstract]   [Full Text] [Related]  

  • 15. Congenital myasthenic syndrome: a tale of two siblings.
    Banerjee A; Datta Kanjilal S; Biswas T; Ghoshal A; Sarkar S
    Int J Neurosci; 2024 Jun; 134(3):253-255. PubMed ID: 36018836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive response to inhaled salbutamol in congenital myasthenic syndrome due to CHRNE mutation.
    Garg D; Goyal V
    Muscle Nerve; 2022 Jul; 66(1):E1-E2. PubMed ID: 35466404
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of salbutamol on neuromuscular junction function and structure in a mouse model of DOK7 congenital myasthenia.
    Webster RG; Vanhaesebrouck AE; Maxwell SE; Cossins JA; Liu W; Ueta R; Yamanashi Y; Beeson DMW
    Hum Mol Genet; 2020 Aug; 29(14):2325-2336. PubMed ID: 32543656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation.
    Lorenzoni PJ; Scola RH; Kay CS; Filla L; Miranda AP; Pinheiro JM; Chaouch A; Lochmüller H; Werneck LC
    J Neurol Sci; 2013 Aug; 331(1-2):155-7. PubMed ID: 23790237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children.
    Tsao CY
    Pediatr Neurol; 2016 Jan; 54():85-7. PubMed ID: 26552645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine.
    Dejthevaporn C; Wetchaphanphesat S; Pulkes T; Rattanasiri S; Engel AG; Witoonpanich R
    J Clin Neurosci; 2022 Feb; 96():85-89. PubMed ID: 34999496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.